Green light for first treatment to target ovarian cancer with BRCA mutation

摘要

The European Medicines Agency (EMA) has recommended that Lyn- parza (olaparib) be approved to combat a type of ovarian cancer for which there are limited treatment options. Ovarian cancer is the fifth most common cause of cancer death in women in the UK. Mortality is high because there are no symptoms in its early stages so most patients are diagnosed at a late stage of the disease. While a proportion of women respond initially to chemotherapy, most relapse and then respond poorly to subsequent chemotherapy.